Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomized ODYSSEY trial.
8 Sep, 2022 | 14:33h | UTC
Commentary on Twitter
New: Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial by Pauline Amuge @bayloruganda and colleagues @MRCCTU https://t.co/mc1jWSXMU2 #openaccess pic.twitter.com/A10LgZcwjF
— The Lancet HIV (@TheLancetHIV) September 1, 2022